Objective To assess the performance of contrastenhanced ultrasound (CE-US)

fluoropyrimidines, platinum agents, and taxanes. Among them, one patient achieved confirmed partial response, and five pts showed stable disease. The most common treatment-related adverse events (!20% of pts) were rash (60%), anemia (30%), neutropenia (30%), thrombocytopenia (20%), and decreased appetite (20%). The second stage is ongoing. Conclusion: TAS-114 with S-1 showed a preliminary efficacy signal with acceptable safety profiles for heavily pretreated pts with AGC, which would be further confirmed in the ongoing study. P À 071 Comparative effectiveness of preoperative, postoperative and perioperative treatments for resectable gastric cancer: A network meta-analysis for the literature of past 20 years

No abstract

found in R0 ressection and pathological complete response (pCR) rates. A significantly higher rate of dose reduction was reported in elderly patients (71.4% vs. 28.6%; p¼0.001). However, no significant differences were found in either treatment delay (50% in both; p¼0.906) or treatment suspension (A: 62.5%, B: 37.5%; p¼0.316). The incidence of grade 3-4 adverse events was similar across the two groups. Nevertheless, a significantly higher rate of grade 3-4 diarrhea (79.6% vs. 23.1%; p¼0.037) and grade 3-4 peripheral neuropathy (80% vs. 20%; p¼0.044) was reported in younger patients. There were two treatment-related deaths, one in each group. The mean progression-free survival (PFS) was 2.6 and 2.8 months in A and B, respectively (95%IC: 1.948-3.178, p¼0.145), while the mean overall survival (OS) was 28.6 and 36.3 months (95%IC: 25.019-39.707, p¼0.090).Conclusions: Perioperative FLOT is safe in elderly patients. A careful dose adjustment may be required to better manage toxicities in these subjects. Dose reductions in this context do not seem to weaken treatment efficacy. Deeper studies are desirable to establish the robustness of these results.Legal entity responsible for the study: The authors.

Introduction: To analysis the molecular pathology characteristics of c-Kit gene and PDGFRA gene mutation in patients with gastrointestinal stromal tumors (GIST) in China. Methods: Retrospectively collect the data of 221 patients with GIST, direct sequencing method was used to test the c-Kit gene and PDGFRA gene mutation. Results: Among the 221 cases, 93.4%, 75.9% and 94.3% with the records of immunophenotypes were positive for CD117, CD34 and DOG-1 respectively. C-kit and PDGFRA gene mutations were found 182 cases (82.4%) and the wild types of the rest 39 cases (17.6%). Among all the c-kit mutation (n = 174), 84.5% mutation types in exon 11(147/174) are deletion mutation, point mutation and hybrid mutations, and 12.6% in exon 9(n = 22), the mutation types are involving duplication and insert, while the other mutation point is 1.7% in exon 13 (n = 3) and 1.1% in exon 17(n = 2). There are 8 patients with the mutation types of PDGFRα in exon 18, and 3 of them are type of D842V.What's more, we found in the secondary resistance patients, the double mutation rate was 35.7% (5/14). Conclusion: The mutation rate of c-Kit gene is high in GIST, and these mutations predominantly occur in exons 11 and 9. The gene mutation test and individualized target treatment is required for the GIST.